HomeAbout usHospitalsSearchLogin
Your medical data, safe and secure.
Name
Stannsoporfin
Description
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Company not known
Stanate